NAD+ IV Therapy: Evidence, Uncertainty, and Safety

Nicotinamide adenine dinucleotide (NAD+) participates in normal cellular energy metabolism and other biochemical processes. Its importance in the body does not, by itself, establish that an NAD+ infusion improves energy, cognition, athletic recovery, longevity, or a medical condition.

What is known

NAD+ and its precursors are actively studied. Research findings about cellular pathways, animal models, oral precursors, or changes in laboratory biomarkers cannot automatically be applied to an IV product or an individual patient.

What remains uncertain

High-quality clinical evidence for many consumer wellness claims remains limited. Appropriate formulation, dose, frequency, long-term effects, and which patients—if any—derive meaningful benefit require further study.

Safety considerations

IV administration can cause pain, bruising, infection, fluid or electrolyte problems, allergic reactions, and ingredient-specific adverse effects. Product source and regulatory status also matter. A clinician should review health history, medicines, allergies, symptoms, and alternatives before treatment.

Questions to ask

• What clinical goal is being evaluated?
• Is there a more established diagnostic or treatment option?
• What evidence applies to this exact formulation and route?
• Is the product compounded, and which pharmacy prepared it?
• What risks, monitoring, and follow-up apply?

Nirvanix does not represent NAD+ IV therapy as a cure or proven anti-aging treatment. Outcomes are not guaranteed.